Members from both UBC and Accredo recently attended NORD’s Rare Diseases and Orphan Products Breakthrough Summit in Arlington, VA. This was a great opportunity for leaders from both organizations to collaborate with key industry stakeholders to discuss the progress as well as challenges in rare disease diagnosis, clinical trials, patient engagement and access to orphan products.
Patient Assistance Program
In recent years, our industry has focused on the critical need to improve the therapeutic journey for patients taking complex specialty medications. Too often, however, delays in therapy initiation can extend days, weeks, or longer, depending on the level of administrative and financial hurdles.
Drug innovation has evolved, drastically changing the way certain diseases are treated. In our latest blog post, Nicole Hebbert, Vice President of Patient Access & Engagement, shares her thoughts on how patient support services have changed over the years.
Oncology patients and products need and deserve specialized care, and that’s best accomplished through a comprehensive service model. UBC’s customized, 360° solution combines expert reimbursement services, an industry-leading Patient Assistance Program model, and compassionate nursing support.
Compassion is good business. That’s why we put the patient at the center of all of our commercial services, including Reimbursement Hubs.
I began my career with UBC as a patient care advocate in our patient assistance call center. Working in the call center gave me the opportunity to have a positive impact on hundreds of lives. There are several patient stories that are special to me, but I’ve carried one patient’s story with me ever since he called to inquire about a PAP two years ago.
There’s a lot of ambiguity around how the government is going to view the private and public exchanges. An OIG opinion providing guidance on whether these plans will be viewed as public versus private plans could have far-reaching implications for how manufacturers provide patient assistance. If we look at some of the OIG guidance offered around Medicare Part D plans and the potential for anti-kickback penalties when offering direct assistance to these beneficiaries, we can start to hypothesize about some of the challenges pharmaceutical manufacturers will face.
The drug pipeline is filled with specialty medications that offer new hope to patients facing complex, chronic conditions. Once these life-saving drugs are approved, a patient still faces many hurdles before beginning a new therapy. A well-designed reimbursement Hub should serve as the center of activity to help patients, caregivers and prescribers navigate administrative obstacles while offering a variety of support services to patients. Here are six questions to ask when considering a Hub:
October is American Pharmacists Month, making it the perfect time for our industry to say “thank you” to pharmacists around the country who work every day to ensure safe, effective medication use. Please join us in celebrating Tara Wesselmann, RPh, a Pharmacist Supervisor in our Patient Assistance Program pharmacy, and the 32 pharmacists on her team. Together, they provide services for programs totaling 8,000 prescriptions each day.